Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Memantine for Neurocognition in CSI (MEMENTO)
NCT06275035Phase 3Recruiting
- Sponsor
- Tata Memorial Centre
- Start
- Feb 2024
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of memantine in neurocognitive disorder (NCD), sponsored by Tata Memorial Centre. Started Feb 2024; status: recruiting.
02
Drugs
memantine
03
Conditions
neurocognitive disorder (NCD)
Beyond the preview
Go deeper on NCT06275035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06275035.